Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection

Vaccines

Maria Pratikaki¹  Anastasia Kotanidou¹  Edison Jahaj¹  Konstantinos N. Syrigos²  Konstantinos Leontis²  Garyphallia Poulakou²  Eleni Kakalou²  Konstantinos Protopapas³  Sotirios Tsiodras³  Anastasia Antoniadou³  Konstantinos Petsios⁴  Angelos Hatzakis⁵  Vana Sypsa⁵  Dimitrios Paraskevis⁵  Sotirios Roussos⁵  Pagona Lagiou⁵  Gkikas Magiorkinis⁵  Dimitrios Basoulis⁶  Helen Gogas⁶  Elpida Mastrogianni⁶  Irene Eliadi⁶  Mina Psichogiou⁶  Antigoni Chaidaroglou⁷  Dimitrios Degiannis⁷  Andreas Karabinis⁷  Ioanna D. Pavlopoulou⁸ 

[1] 1st Department of Critical Care & Pulmonary Services, Medical School, National and Kapodistrian University of Athens, Evangelismos Hospital, 10676 Athens, Greece;3rd Department of Internal Medicine, Sotiria General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece;Clinical Research Office, Onassis Cardiac Surgery Center, 17674 Athens, Greece;Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;Onassis Cardiac Surgery Center, 17674 Athens, Greece;Pediatric Research Laboratory, Faculty of Nursing, National and Kapodistrian University of Athens, 11527 Athens, Greece;

关键词: COVID-19;    BNT162b2 vaccine;    health care workers;    immune response;    anti-RBD;   

DOI  :  10.3390/vaccines9091017

来源: DOAJ

【 摘 要 】

BNT162b2 has proven to be highly effective, but there is a paucity of data regarding immunogenicity factors and comparison between response to vaccination and natural infection. This study included 871 vaccinated healthcare workers (HCW) and 181 patients with natural infection. Immunogenicity was assessed by measuring anti-SARS-CoV-2 against the RBD domain of the spike protein (anti-RBD). Samples were collected 1–2 weeks after vaccination or 15–59 days post-onset of symptoms. Post-vaccine anti-RBD concentrations were associated with age, gender, vaccination side-effects (VSE) and prior infection (Pr-CoV). Anti-RBD median levels (95%CI) were lower by 2466 (651–5583), 6228 (3254–9203) and 7651 (4479–10,823) AU/mL in 35–44, 45–54, 55–70 yrs, respectively, compared with the 18–34 yrs group. In females, the median levels were higher by 2823 (859–4787), 5024 (3122–6926) in individuals with VSE, and 9971 (5158–14,783) AU/mL in HCWs with Pr-CoV. The ratio of anti-RBD in vaccinated individuals versus those with natural infection varied from 1.0 to 19.4. The high immunogenicity of BNT162b2 is verified, although its sustainability has yet to be elucidated. The use of comparative data from natural infection serological panels, expressing the clinical heterogeneity of natural infection, may facilitate early decisions for candidate vaccines to be evaluated in clinical trials.

【 授权许可】

Unknown